Melissa M. Yoon
Consigliere Generale presso Ambry Genetics Corp.
Profilo
Melissa M.
Yoon is currently the General Counsel at Ambry Genetics Corp.
She previously worked as a Secretary at Akcea Therapeutics, Inc.
Posizioni attive di Melissa M. Yoon
| Società | Posizione | Inizio |
|---|---|---|
Ambry Genetics Corp.
 Ambry Genetics Corp. Miscellaneous Commercial ServicesCommercial Services Ambry Genetics Corp. provides clinical genetic diagnostics and genetics software solutions. Its services include clinical diagnostics tests, forms, billing, order kits, patient resources about cancer, cardiology, billing information and research and collaboration services. The company was founded by Charles L.M. Dunlop and James Dunlop in 1999 and is headquartered in Aliso Viejo, CA. | Consigliere Generale | - |
Precedenti posizioni note di Melissa M. Yoon
| Società | Posizione | Fine |
|---|---|---|
| AKCEA THERAPEUTICS, INC. | Segretario Aziendale | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 2 |
|---|---|
Ambry Genetics Corp.
Ambry Genetics Corp. Miscellaneous Commercial ServicesCommercial Services Ambry Genetics Corp. provides clinical genetic diagnostics and genetics software solutions. Its services include clinical diagnostics tests, forms, billing, order kits, patient resources about cancer, cardiology, billing information and research and collaboration services. The company was founded by Charles L.M. Dunlop and James Dunlop in 1999 and is headquartered in Aliso Viejo, CA. | Commercial Services |
Akcea Therapeutics, Inc.
 Akcea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Akcea Therapeutics, Inc. is a biopharmaceutical company. It engages in the development and marketing of drugs globally to treat patients with rare and serious diseases using antisense technology. Its primary focus is developing TEGSEDI, a therapy that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. It also offers a mature pipeline of novel drugs including AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, and AKCEA-APOCIII-LRx. The company was founded in December 2014 and is headquartered in Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- Melissa M. Yoon
